Product
Pretomanid
Aliases
Pa, PA-824
Name
Pretomanid
INN Name
Pretomanid
FDA Approved
Yes
11 clinical trials
1 organization
10 indications
1 document
Indication
Multidrug-resistant TuberculosisIndication
Extensively Drug-Resistant TuberculosisIndication
Pulmonary TuberculosisIndication
TuberculosisIndication
PulmonaryIndication
Multidrug-resistantIndication
Drug Sensitive TuberculosisIndication
Pre-XDR-TBIndication
Multidrug-resistant tuberculosisClinical trial
Economic Evaluation of New MDR TB Regimens (PRACTECAL EE)Status: Completed, Estimated PCD: 2022-08-25
Clinical trial
A Seamless Phase 2B/C Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary TuberculosisStatus: Recruiting, Estimated PCD: 2027-02-24
Clinical trial
A Phase 2b/c, Multi-Arm, 2-Stage, Duration Randomized Trial of the Efficacy and Safety of Two to Four Months Treatment With Regimens Containing Bedaquiline, OPC-167832, and Sutezolid, Plus Either Pretomanid or Delamanid, in Adults With Pulmonary TuberculosisStatus: Recruiting, Estimated PCD: 2027-10-01
Clinical trial
An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)Status: Completed, Estimated PCD: 2021-07-01
Clinical trial
A Novel 4-month Pan-TB Regimen Targeting Both Host and Microbe (panTB-HM)Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisStatus: Not yet recruiting, Estimated PCD: 2025-06-10
Clinical trial
An Open-Label Phase 2 Trial to Evaluate the Male Reproductive Safety of a 6-Month Combination Treatment for Pulmonary Tuberculosis (TB) of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) in Adult Male Participants With Drug Resistant Pulmonary TBStatus: Active (not recruiting), Estimated PCD: 2023-06-19
Clinical trial
A Phase 3 Partially-blinded, Randomized Trial Assessing the Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis (XDR-TB), Pre-XDR-TB or Treatment Intolerant or Non-responsive Multi-drug Resistant Tuberculosis (MDR-TB)Status: Completed, Estimated PCD: 2021-02-15
Clinical trial
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)Status: Not yet recruiting, Estimated PCD: 2029-06-30
Clinical trial
A Phase 2, Partially-blinded, Randomised Trial Assessing the Safety and Efficacy of TBAJ-876 or Bedaquiline, in Combination With Pretomanid and Linezolid in Adult Participants With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary TuberculosisStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical TrialStatus: Completed, Estimated PCD: 2022-05-10
Document
DailyMed Label: PretomanidOrganization
Mylan Specialty L.P.